Quantcast
Home > Quotes > OGEN

Oragenics Inc. Common Stock (OGEN) Quote & Summary Data

OGEN 
$0.98
*  
0.01
1.03%
Get OGEN Alerts
*Delayed - data as of Jan. 18, 2019  -  Find a broker to begin trading OGEN now
Exchange:AMEX
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

1 Year Target
5
Today's High / Low
$ 0.99 / $ 0.9501
Share Volume
918,707
90 Day Avg. Daily Volume
6,419,030
Previous Close
$ 0.97
52 Week High / Low
$ 4.20 / $ 0.38
Market Cap
28,844,472
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
2.8

Intraday Chart

Shares Traded

Share Volume:
918,707
90 Day Avg. Daily Volume:
6,419,030

Trading Range

The current last sale of $0.98 is 157.89% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.99 $ 4.20
 Low: $ 0.9501 $ 0.38

Company Description (as filed with the SEC)

This description contains certain forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from the results discussed in the forward-looking statements as a result of certain of the risks set forth herein. We assume no obligation to update any forward-looking statements contained herein. Overview We are focused on becoming a leader in developing novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Our Oral Mucositis Product Candidate-Clinical In June of 2015, we entered into a worldwide Exclusive Channel Collaboration Agreement ("Oral Mucositis ECC") with Intrexon Corporation ("Intrexon") and Intrexon Actobiotics NV, a wholly-owned subsidiary of Intrexon, pursuant to which we obtained certain exclusive rights to AG013 as a potential treatment of oral mucositis, or OM for cancer patients, which we intend to continue to develop.  ... More ...  

Research Brokers before you trade

Want to trade FX?

Analyst Info